nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.04.2014 | Original Article

Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on ¹⁸F-florbetapir (AV-45/Amyvid) positron emission tomography

verfasst von: Kuan-Yi Wu, Ing-Tsung Hsiao, Cheng-Sheng Chen, Chia-Hsiang Chen, Chia-Ju Hsieh, Yau-Yau Wai, Chee-Jen Chang, Hsiao-Jung Tseng, Tzue-Chen Yen, Chia-Yih Liu, Kun-Ju Lin

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The literature suggests that a history of depression is associated with an increased risk of developing Alzheimer’s disease (AD). The aim of this study was to examine brain amyloid accumulation in patients with lifetime major depression using ¹⁸F-florbetapir (AV-45/Amyvid) PET imaging in comparison with that in nondepressed subjects.

Methods

The study groups comprised 25 depressed patients and 11 comparison subjects who did not meet the diagnostic criteria for AD or amnestic mild cognitive impairment. Vascular risk factors, homocysteine and apolipoprotein E (ApoE) genotype were also examined. The standard uptake value ratio (SUVR) of each volume of interest was analysed using whole the cerebellum as the reference region.

Results

Patients with a lifetime history of major depression had higher ¹⁸F-florbetapir SUVRs in the precuneus (1.06 ± 0.08 vs. 1.00 ± 0.06, p = 0.045) and parietal region (1.05 ± 0.08 vs. 0.98 ± 0.07, p = 0.038) than the comparison subjects. Voxel-wise analysis revealed a significantly increased SUVR in depressed patients in the frontal, parietal, temporal and occipital areas (p < 0.01). There were no significant associations between global ¹⁸F-florbetapir SUVRs and prior depression episodes, age at onset of depression, or time since onset of first depression.

Conclusion

Increased ¹⁸F-florbetapir binding values were found in patients with late-life major depression relative to comparison subjects in specific brain regions, despite no differences in age, sex, education, Mini Mental Status Examination score, vascular risk factor score, homocysteine and ApoE ε4 genotype between the two groups. A longitudinal follow-up study with a large sample size would be worthwhile.

Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63:530–8.PubMedCentralPubMedCrossRef

Jorm AF. History of depression as a risk factor for dementia: an updated review. Aust N Z J Psychiatr. 2001;35:776–81.CrossRef

Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol. 2003;60:753–9.PubMedCrossRef

Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry. 2004;75:1662–6.PubMedCentralPubMedCrossRef

Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, Purohit DP, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006;63:161–7.PubMedCrossRef

Geerlings MI, Schoevers RA, Beekman AT, Jonker C, Deeg DJ, Schmand B, et al. Depression and risk of cognitive decline and Alzheimer’s disease. Results of two prospective community-based studies in The Netherlands. Br J Psychiatry. 2000;176:568–75.PubMedCrossRef

Nilsson FM, Kessing LV, Sørensen TM, Andersen PK, Bolwig TG. Enduring increased risk of developing depression and mania in patients with dementia. J Neurol Neurosurg Psychiatry. 2002;73:40–4.PubMedCentralPubMedCrossRef

Klunk WE, Wang Y, Huang G-F, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69:1471–84.PubMedCrossRef

Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatr. 2002;10:24–35.CrossRef

10.

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–63.PubMedCrossRef

11.

Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F18). J Nucl Med. 2010;51:913–20.PubMedCentralPubMedCrossRef

12.

Butters MA, Klunk WE, Mathis CA, Price JC, Ziolko SK, Hoge JA, et al. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord. 2008;22:261–8.PubMedCentralPubMedCrossRef

13.

Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397–401.PubMed

14.

Butters MA, Whyte EM, Nebes RD, Begley AE, Dew MA, Mulsant BH, et al. The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry. 2004;61:587–95.PubMedCrossRef

15.

Yeh YC, Tsang HY, Lin PY, Kuo YT, Yen CF, Chen CC, et al. Subtypes of mild cognitive impairment among the elderly with major depressive disorder in remission. Am J Geriatr Psychiatr. 2011;19:923–31.CrossRef

16.

Lopez OL, Jagust WJ, DeKosky ST, Becker JT, Fitzpatrick A, Dulberg C, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1. Arch Neurol. 2003;60:1385–9.PubMedCrossRef

17.

Lee JS, Potter GG, Wagner HR, Welsh-Bohmer KA, Steffens DC. Persistent mild cognitive impairment in geriatric depression. Int Psychogeriatr. 2007;19:125–35.PubMedCrossRef

18.

Irizarry M, Gurol M, Raju S, Diaz-Arrastia R, Locascio J, Tennis M, et al. Association of homocysteine with plasma amyloid β protein in aging and neurodegenerative disease. Neurology. 2005;65:1402–8.PubMedCrossRef

19.

Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277–81.PubMedCrossRef

20.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.PubMedCrossRef

21.

Lin RT, Lai CL, Tai CT, Liu CK, Yen YY, Howng SL. Prevalence and subtypes of dementia in southern Taiwan: impact of age, sex, education, and urbanization. J Neurol Sci. 1998;160:67–75.PubMedCrossRef

22.

Liu CK, Lin RT, Chen YF, Tai CT, Yen YY, Howng SL. Prevalence of dementia in an urban area in Taiwan. J Formos Med Assoc. 1996;95:762–8.PubMed

23.

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8.PubMedCrossRef

24.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.PubMedCrossRef

25.

Spitzer M, Robert L, Gibbon M, Williams J. Structured clinical interview for DSM-IV-TR axis I disorders, research version, non-patient edition (SCID-I/NP). New York: Biometrics Research, New York State Psychiatric Institute; 2002.

26.

Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–92.PubMedCrossRef

27.

Huang KL, Lin KJ, Hsiao IT, Kuo HC, Hsu WC, Chuang WL, et al. Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer’s disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. PLoS One. 2013;8:e58974.PubMedCentralPubMedCrossRef

28.

Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.PubMedCentralPubMedCrossRef

29.

Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312–8.PubMedCrossRef

30.

Licastro F, Pedrini S, Ferri C, Casadei V, Govoni M, Pession A, et al. Gene polymorphism affecting α1–antichymotrypsin and interleukin–1 plasma levels increases Alzheimer’s disease risk. Ann Neurol. 2001;48:388–91.CrossRef

31.

Yao CH, Lin KJ, Weng CC, Hsiao IT, Ting YS, Yen TC, et al. GMP-compliant automated synthesis of [(18)F]AV-45 (Florbetapir F18) for imaging beta-amyloid plaques in human brain. Appl Radiat Isot. 2010;68:2293–7.PubMedCrossRef

32.

Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent – a pilot study. Nucl Med Biol. 2010;37:497–508.PubMedCrossRef

33.

Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89.PubMedCrossRef

34.

Hsiao IT, Huang CC, Hsieh CJ, Hsu WC, Wey SP, Yen TC, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. Eur J Nucl Med Mol Imaging. 2012;39:613–20.PubMedCrossRef

35.

Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839–51.PubMedCrossRef

36.

Madsen K, Hasselbalch BJ, Frederiksen KS, Haahr ME, Gade A, Law I, et al. Lack of association between prior depressive episodes and cerebral [11C]PiB binding. Neurobiol Aging. 2012;33:2334–42.PubMedCrossRef

37.

Camus V, Payoux P, Barré L, Desgranges B, Voisin T, Tauber C, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39:621–31.PubMedCentralPubMedCrossRef

38.

Driscoll I, Zhou Y, An Y, Sojkova J, Davatzikos C, Kraut MA, et al. Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiol Aging. 2011;32:2123–30.PubMedCentralPubMedCrossRef

39.

Lavretsky H, Siddarth P, Kepe V, Ercoli LM, Miller KJ, Burggren AC, et al. Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am J Geriatr Psychiatr. 2009;17:493–502.CrossRef

40.

Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O’Keefe G, et al. Imaging of amyloid β in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129–35.PubMedCrossRef

41.

Ziolko SK, Weissfeld LA, Klunk WE, Mathis CA, Hoge JA, Lopresti BJ, et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer’s disease. Neuroimage. 2006;33:94–102.PubMedCrossRef

42.

Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351–7.PubMedCrossRef

43.

Braak H, Braak E. Staging of Alzheimer-related cortical destruction. Int Psychogeriatr. 1997;9 Suppl 1:257–61.PubMedCrossRef

44.

Cavanna AE, Trimble MR. The precuneus: a review of its functional anatomy and behavioural correlates. Brain. 2006;129:564–83.PubMedCrossRef

45.

Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer’s disease. J Neurosci. 2006;26:9047–56.PubMedCrossRef

46.

Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-β via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A. 2007;104:10673–8.PubMedCentralPubMedCrossRef

47.

Devanand DP, Folz M, Gorlyn M, Moeller JR, Stern Y. Questionable dementia: clinical course and predictors of outcome. J Am Geriatr Soc. 1997;45:321–8.PubMed

48.

Yesavage JA, O’Hara R, Kraemer H, Noda A, Taylor JL, Ferris S, et al. Modeling the prevalence and incidence of Alzheimer’s disease and mild cognitive impairment. J Psychiatr Res. 2002;36:281–6.PubMedCrossRef

49.

Levine 3rd H, Walker LC. Molecular polymorphism of Aβ in Alzheimer’s disease. Neurobiol Aging. 2010;31:542–8.PubMedCentralPubMedCrossRef

50.

Gearing M, Mirra SS, Hedreen JC, Sumi SM, Hansen LA, Heyman A. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer’s disease. Neurology. 1995;45:461–6.PubMedCrossRef

51.

Pearl GS. Diagnosis of Alzheimer’s disease in a community hospital-based brain bank program. South Med J. 1997;90:720–2.PubMedCrossRef

Titel: Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography
verfasst von: Kuan-Yi Wu
Ing-Tsung Hsiao
Cheng-Sheng Chen
Chia-Hsiang Chen
Chia-Ju Hsieh
Yau-Yau Wai
Chee-Jen Chang
Hsiao-Jung Tseng
Tzue-Chen Yen
Chia-Yih Liu
Kun-Ju Lin
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2627-0

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Molecular imaging of brown adipose tissue in health and disease

Suboptimal use of imaging in the new (National Comprehensive Cancer Network) International Prognostic Index for diffuse large B-cell lymphoma

Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma

Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone

Imaging of amyloid deposition in human brain using positron emission tomography and [18F]FACT: comparison with [11C]PIB

Differentiation of HIV-associated lymphoma from HIV-reactive adenopathy using quantitative FDG-PET and symmetry